Arrien Pharmaceuticals applies its proprietary platform to discover a portfolio of pre-clinical stage programs in Parkinson's, Alzheimer's Diseases, Cancer, Rheumatoid Arthritis, Type 2 Diabetes, and Obesity. The company aims to develop small molecules that target protein kinase signaling, nuclear hormone receptor, and immuno-oncology/checkpoint pathway targets for the treatment of human cancers, autoimmune, and neurodegenerative diseases.